Patents by Inventor Barbara Johnson
Barbara Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10271644Abstract: A support rod storage securing system includes a container for holding clothing that has a bottom wall and a perimeter wall that is attached to and extending upwardly from the bottom wall. The perimeter wall has an upper edge defining an opening extending into the container. A frame member is mounted to the container. A collapsible dressing station is removably mountable to the container such that the collapsible dressing station extends upwardly from the container. The collapsible dressing station includes an upper bar configured to receive clothes hangers. A pair of connectors each is attached to the frame member. The upper bar is removably mounted on the pair of connectors such that the upper bar is releasably retained in a static position within the container.Type: GrantFiled: March 16, 2018Date of Patent: April 30, 2019Inventor: Barbara Johnson
-
Publication number: 20180051089Abstract: The present invention relates to a TCR KO—or TCR KO and dCK KO—engineered immune cells expressing a Chimeric Antigen Receptors (CAR) specific for CD123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward CD123-expressing cells, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CD123 CARs are particularly suited for treating relapse refractory AML and blastic plasmacytoid dendritic cell neoplasm and for use as a treatment before bone marrow transplantation.Type: ApplicationFiled: January 25, 2016Publication date: February 22, 2018Inventors: Roman GALETTO, Barbara Johnson SASU, Arvind RAJPAL, Philippe DUCHATEAU, Alexandre JUILLERAT, Julien VALTON, Mathieu SIMON
-
Publication number: 20180002435Abstract: A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.Type: ApplicationFiled: January 25, 2016Publication date: January 4, 2018Inventors: Barbara Johnson SASU, Arvind RAJPAL, Philippe DUCHATEAU, Alexandre JUILLERAT, Julien VALTON
-
Patent number: 9179721Abstract: The invention concerns a wig or lace wig cap, to be worn by the user underneath a wig or lace wig. The cap is comprised of a plurality of panels using stretchable and breathable material, an elasticized banding and a plurality of sew on snap fasteners affixed to, said banding to form the Press and Go Wig and Lace Wig Snap Cap. Cooperating snaps are then affixed to a wig or lace wig around the entire circumference of the outer inside wig weft, concealing the application process, thereby producing a comfortable, airy and secure fit to the user. An additional banding is included, affixed with a plurality of snap fasteners designed to fit cooperating snaps of a wig or lace wig. Also included is a tension strap affixed with two cooperating snap fasteners designed to be used as an adjustment strap to the cap banding or separate banding.Type: GrantFiled: October 31, 2013Date of Patent: November 10, 2015Inventors: Barbara Johnson Hines, Tonnette Williams Hill, Darryl Wayne Williams
-
Publication number: 20150114415Abstract: The invention concerns a wig or lace wig cap, to be worn by the user underneath a wig or lace wig. The cap is comprised of a plurality of panels using stretchable and breathable material, an elasticized banding and a plurality of sew on snap fasteners affixed to, said banding to form the Press and Go Wig and Lace Wig Snap Cap. Cooperating snaps are then affixed to a wig or lace wig around the entire circumference of the outer inside wig weft, concealing the application process, thereby producing a comfortable, airy and secure fit to the user. An additional banding is included, affixed with a plurality of snap fasteners designed to fit cooperating snaps of a wig or lace wig. Also included is a tension strap affixed with two cooperating snap fasteners designed to be used as an adjustment strap to the cap banding or separate banding.Type: ApplicationFiled: October 31, 2013Publication date: April 30, 2015Inventors: Barbara Johnson Hines, Tonnette Williams Hill, Darryl Wayne Williams
-
Patent number: 7790197Abstract: A wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof with less than about 5 weight % of an alkaline earth metal salt additive with a disintegrant which provides the atorvastatin with not more than about 3% atorvastatin lactone based on the ratio of lactone peak area compared to the total drug-related peak integrated areas, as well as said wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical compositions.Type: GrantFiled: April 20, 2004Date of Patent: September 7, 2010Assignee: Warner-Lambert Company LLCInventors: Michael B. Fergione, Barbara A. Johnson, Kenneth Craig Waterman
-
Publication number: 20100048498Abstract: This invention relates to a powder for oral suspension, and an oral suspension made there from, which comprises non-dihydrate azithromycin and an azithromycin conversion stabilizing excipient, wherein said excipient reduces the conversion of the form of azithromycin, when placed in suspension, to another form of azithromycin. This invention further relates to a method for reducing the conversion of a form of non-dihydrate azithromycin, in an oral suspension, by including at least one cyclodextrin in said oral suspension.Type: ApplicationFiled: December 9, 2005Publication date: February 25, 2010Inventors: Barbara A. Johnson, Brendan J. Murphy
-
Patent number: 7438924Abstract: This invention relates to a pharmaceutical formulation, in the form of a tablet, sachet or powder for suspension dosage form, which comprises dry granulated particles of a non-dihydrate form of azithromycin and, optionally, one or more pharmaceutically acceptable excipients. Preferably, the pharmaceutical formulation is a tablet containing between about 40%, by weight, to about 90%, by weight, non-dihydrate azithromycin. More preferably, the pharmaceutical formulation contains non-dihydrate azithromycin selected from the forms B, D, E, F, G, H, J, M, N, O, P, Q, R, or mixtures thereof. Even more preferably, the invention relates to a pharmaceutical formulation wherein the dosage of azithromycin is 250 mgA, 500 mgA, 600 mgA or 1000 mgA. The present invention further relates to a dry granulated azithromycin particle, comprising a form of azithromycin, selected from forms D, E, F, G, H, J, M, N, O, P, Q, R and mixtures of non-dihydrate forms, and at least one pharmaceutically acceptable excipient.Type: GrantFiled: January 31, 2003Date of Patent: October 21, 2008Assignee: Pfizer IncInventors: Barbara A. Johnson, Ernest S. Quan
-
Patent number: 7415510Abstract: A system and a method for indexing pedestrian traffic are disclosed. Traffic information is gathered from counter units (30, 31) placed at entrances in provider malls, retail stores, or other locations where pedestrians may be counted. The counters give daily reports to the traffic indexing system (40) of the amount of pedestrian traffic flowing through traffic monitoring points (30, 31). Traffic data are collected daily from providers and compiled into an index (40). These data may be integrated and indexed with other data such as sales data, labor data and promotion data. Providers (30, 31) and other users (45) may access the traffic index (40) along with other industry information to gauge their performance as compared to the performance of others in the industry or to make educated decisions on development and marketing issues.Type: GrantFiled: March 17, 2000Date of Patent: August 19, 2008Assignee: Shoppertrack RCT CorporationInventors: George Kramerich, Barbara Johnson, Krista Diberardino, William Jackewicz, James Martin, Andrew Voss
-
Publication number: 20080145427Abstract: A dosage form that includes a cholesteryl ester transfer protein inhibitor in a solubility-improved form and an HMG-CoA reductase inhibitor, wherein the dosage form provides immediate release of the HMG-CoA reductase inhibitor and controlled release and immediate release of the cholesteryl ester transfer protein inhibitor.Type: ApplicationFiled: January 23, 2006Publication date: June 19, 2008Inventors: Alfred Berchielli, Eric K. Eisenhart, Scott M. Herbig, Barbara A. Johnson
-
Publication number: 20070275890Abstract: Methods of use of Chaperonin 10 (Cpn10) are provided for regulating Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. Cpn10 negatively regulates Toll-like receptor agonist-induced pro-inflammatory cytokine and chemokine secretion, examples being IL-6 and RANTES, respectively. Cpn10 positively regulates Toll-like receptor agonist-induced anti-inflammatory cytokine and chemokine secretion, an example being IL-10. These immunoregulatory activities of Cpn10 may be useful in the treatment of diseases, disorders and conditions resulting from excessive pro-inflammatory cytokine and chemokine secretion. This invention also relates to producing, designing and/or screening Cpn10 agonists and antagonists according to their ability to regulate Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion.Type: ApplicationFiled: January 14, 2005Publication date: November 29, 2007Inventors: Barbara Johnson, Andreas Suhrbier, Dean Naylor, Caroline Dobbin, Christopher Howard
-
Patent number: 7070811Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.Type: GrantFiled: July 26, 2005Date of Patent: July 4, 2006Assignee: Pfizer Inc.Inventors: Brendan Murphy, Steven W. Collier, Ernest Quan, Barbara A. Johnson
-
Publication number: 20060084656Abstract: A composition for nasal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient. The invention also provides a composition for buccal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient to form a solid dosage form, wherein the solid dosage form disintegrates in an oral cavity at body temperature and may adhere to body tissue of the oral cavity; a composition for pulmonary administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient; and, a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject.Type: ApplicationFiled: October 14, 2005Publication date: April 20, 2006Inventors: Carl Ziegler, Barbara Johnson
-
Publication number: 20060057207Abstract: A fast disintegrating dosage form of varenicline comprising an effective amount of varenicline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form disintegrates in a patient's oral cavity in less than three minutes. Also provided are a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject by administering to the subject an effective amount of the fast disintegrating dosage form of varenicline or pharmaceutically acceptable salts thereof; a method of treating a disorder or condition by administering an effective amount of the fast disintegrating dosage form of varenicline; and, various methods of manufacturing or forming an immediate dosage form of varenicline.Type: ApplicationFiled: November 8, 2005Publication date: March 16, 2006Inventors: Carl Ziegler, Barbara Johnson
-
Publication number: 20060024364Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.Type: ApplicationFiled: August 26, 2005Publication date: February 2, 2006Inventors: Brendan Murphy, Steven Collier, Ernest Quan, Barbara Johnson
-
Publication number: 20060024363Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.Type: ApplicationFiled: August 26, 2005Publication date: February 2, 2006Inventors: Brendan Murphy, Steven Collier, Ernest Quan, Barbara Johnson
-
Publication number: 20050287209Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.Type: ApplicationFiled: July 26, 2005Publication date: December 29, 2005Inventors: Brendan Murphy, Steven Collier, Ernest Quan, Barbara Johnson
-
Publication number: 20050013835Abstract: This invention relates to a powder for oral suspension, and an oral suspension made therefrom, which comprises non-dihydrate azithromycin and an azithromycin conversion stabilizing excipient, wherein said excipient reduces the conversion of the form of azithromycin, when placed in suspension, to another form of azithromycin. This invention further relates to a method for reducing the conversion of a form of non-dihydrate azithromycin, in an oral suspension, by adding a surface tension reducing excipient that reduces the surface tension of the aqueous vehicle. Furthermore, this invention relates to a method for reducing the conversion of a non-dihydrate azithromycin, in an unflavored oral suspension, by raising the viscosity of the oral suspension, and in a flavored oral suspension by lowering the viscosity of the oral suspension.Type: ApplicationFiled: August 6, 2003Publication date: January 20, 2005Inventors: Steven Collier, William Curatolo, Barbara Johnson, Brendan Murphy
-
Publication number: 20040247673Abstract: A wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof with less than about 5 weight % of an alkaline earth metal salt additive with a disintegrant which provides the atorvastatin with not more than about 3% atorvastatin lactone based on the ratio of lactone peak area compared to the total drug-related peak integrated areas, as well as said wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical compositions.Type: ApplicationFiled: April 20, 2004Publication date: December 9, 2004Inventors: Michael B. Fergione, Barbara A. Johnson, Kenneth Craig Waterman
-
Patent number: D849516Type: GrantFiled: March 16, 2018Date of Patent: May 28, 2019Inventor: Barbara Johnson